Clinical Trial Update: The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the effect of triheptanoin on fatty acid oxidation and exercise tolerance in patients with Tarui disease and debrancher deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Debrancher Deficiency
• Gyg1 Deficiency
• Tarui Disease

Drugs mentioned

• Triheptanoin (triheptanoin)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Tarui Disease, Debrancher Deficiency | Phase 2 | Status: COMPLETED